Save 30% with brand Arzerra
Information about Arzerra (Ofatumumab):
Arzerra (Ofatumumab) is a CD20-directed cytolytic monoclonal antibody used in the treatment of chronic lymphocytic leukemia (CLL). Its indications include:
- Combination with Chlorambucil: Combine use for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate.
- Combination with Fludarabine and Cyclophosphamide: Combine use for the treatment of patients with relapsed CLL.
- For Extended Treatment: For patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.
- For CLL Refractory to Fludarabine and Alemtuzumab: For the treatment of patients with CLL that is refractory to both fludarabine and alemtuzumab.
It is a monoclonal antibody that targets and binds to CD20, a protein found on the surface of B-cells. It is indicated for the treatment of chronic lymphocytic leukemia (CLL) and some other B-cell malignancies. Specifically, it is used in combination with other therapies or as a monotherapy for patients with relapsed or refractory CLL.
Product Highlights
- Arzerra is typically available in form of intravenous infusion.
- Administered by a healthcare professional in a clinical setting.
- Arzerra, a fully human monoclonal antibody targeting CD20 on B-cells.
Key Ingredients
- Ofatumumab
- Diluted hydrochloric acid
- Edetate disodium
- Sodium acetate
- Polysorbate
Key Benefits
- Arzerra helps target and destroy malignant B-cells, which can lead to significant tumor reduction and improved clinical outcomes.
- It provides an option for patients whose cancer has not responded to other treatments.
- When used with other drugs, it can enhance the overall effectiveness of treatment regimens for CLL.
Direction For Use
- Arzerra is given by intravenous infusion. The infusion process typically starts slowly and is monitored for any adverse reactions.
- The frequency and duration of infusions depend on the specific treatment protocol and patient response.
- The infusion must be prepared and administered by trained healthcare professionals.
Safety Concern
- Common side effects can include infusion-related reactions such as fever, chills, and nausea. Premedication with antihistamines and antipyretics may be recommended to mitigate these reactions.
- Arzerra can increase the risk of infections, including serious bacterial, fungal, and viral infections.
- There may be an impact on blood counts, leading to potential complications like neutropenia or thrombocytopenia.
- Patients should be monitored for potential risks including hepatitis B reactivation and autoimmune conditions.
Avoid Arzerra (Ofatumumab) If
- If you have a known hypersensitivity or allergic reaction to Arzerra or any of its components, it should be avoided.
- It should not be administered to patients with active or severe infections until the infection is adequately controlled.
- The safety of Arzerra during pregnancy has not been well established, so it should generally be avoided unless clearly needed and prescribed by a healthcare provider.
